Company intelligence / Profile preview

Coeurative, Inc.

Roanoke, Virginia, United Statescoeurative.com ↗

Ownership: Private
Employees: ~2
Development stage: Phase 3

Overview

Coeurative has developed patented compounds that deliver and generate nitric oxide in vascular endothelial cells. Early experiments suggest these drugs are more effective at dilating human coronary arteries than currently available generic NO donors. The company is expanding preclinical studies with the goal of completing initial drug development phases and filing an IND application within three years as of January 2024.

Therapeutic areas: Cardiovascular
Modalities: Small molecules (novel nitric oxide donors/generators)
Industry: Biotech

Drug pipeline

3 assets

CR-0305

Preclinical

2 more assets in the full pipeline.

Partnerships

National Heart, Lung, and Blood Institute (SBIR award recipient)

Beyond the preview

Go deeper on Coeurative, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coeurative, Inc..